IL-22 also activates STAT3 in epithelial cells to promote tissue repair.24 Previous studies have shown that tofacitinib inhibits IL-22-driven STAT3 phosphorylation in human colonic epithelial organoids and impairs epithelial repair in a DSS-colitis model.44,45 However, in C. jejuni colitis model, IL-22 expression remained unchanged in the colon tissue in both tofacitinib- and vehicle-treated groups. This evidence concerns the gene STAT3 and colitis.